Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells $149,837.04 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,026 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $149,837.04. Following the transaction, the insider now directly owns 144,782 shares in the company, valued at approximately $21,143,963.28. This represents a 0.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total value of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Price Performance

Shares of NASDAQ NTRA opened at $151.15 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $161.23 and its 200 day moving average price is $149.50. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The stock has a market cap of $20.43 billion, a price-to-earnings ratio of -85.88 and a beta of 1.80.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. As a group, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Barclays initiated coverage on shares of Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective for the company. Sanford C. Bernstein boosted their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. The Goldman Sachs Group raised their price target on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, JPMorgan Chase & Co. upped their price objective on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $178.12.

Institutional Trading of Natera

Institutional investors and hedge funds have recently made changes to their positions in the stock. Apollon Wealth Management LLC acquired a new position in Natera in the 3rd quarter valued at about $270,000. KBC Group NV raised its position in shares of Natera by 15.7% in the third quarter. KBC Group NV now owns 3,227 shares of the medical research company’s stock valued at $410,000 after buying an additional 439 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after buying an additional 111 shares during the last quarter. Natixis Advisors LLC lifted its stake in shares of Natera by 26.3% during the third quarter. Natixis Advisors LLC now owns 31,051 shares of the medical research company’s stock valued at $3,942,000 after buying an additional 6,467 shares during the period. Finally, Thrivent Financial for Lutherans boosted its position in Natera by 1.2% during the third quarter. Thrivent Financial for Lutherans now owns 143,903 shares of the medical research company’s stock worth $18,269,000 after acquiring an additional 1,685 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.